KR102179155B1 - Osteogenesis method by Jade extract in ADSC - Google Patents

Osteogenesis method by Jade extract in ADSC Download PDF

Info

Publication number
KR102179155B1
KR102179155B1 KR1020200068870A KR20200068870A KR102179155B1 KR 102179155 B1 KR102179155 B1 KR 102179155B1 KR 1020200068870 A KR1020200068870 A KR 1020200068870A KR 20200068870 A KR20200068870 A KR 20200068870A KR 102179155 B1 KR102179155 B1 KR 102179155B1
Authority
KR
South Korea
Prior art keywords
cells
bone
jade
stem cells
skin
Prior art date
Application number
KR1020200068870A
Other languages
Korean (ko)
Inventor
진교식
이승관
김보용
박윤진
Original Assignee
진교식
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진교식 filed Critical 진교식
Priority to KR1020200068870A priority Critical patent/KR102179155B1/en
Application granted granted Critical
Publication of KR102179155B1 publication Critical patent/KR102179155B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/13Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323Adult fibroblasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1384Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a method for differentiating bone cells of stem cells by a jade extract. More specifically, the present invention relates to a method for differentiating bone cells of stem cells by a jade extract and a composition for restoring skin cells or treating arthritis and a cosmetic composition containing bone cells manufactured by the method, wherein the method comprises the following steps: 1) treating the jade extract to skin cells to discharge activated functional ingredients; 2) separating a supernatant of a medium containing the functional ingredients; 3) treating the separated medium supernatant to stem cells and culturing the same to differentiate into bone cells; and 4) separating the differentiated bone cells. When using the method for differentiating bone cells, adipose-derived stem cells can be differentiated into bone cells. Therefore, the promotion of bone cell differentiation according to the present invention can be effectively used for bone development of infants in a growth period and prevention of osteoporosis in the middle-aged. In addition, bone cells obtained according to the present invention can be usefully used in the treatment of skin disease such as general scars and burn scars, and bone metabolic diseases such as bone defect part procedures.

Description

옥추출물을 이용한 골세포 분화 방법 {Osteogenesis method by Jade extract in ADSC}Bone cell differentiation method using jade extract {Osteogenesis method by Jade extract in ADSC}

본 발명은 옥추출물을 이용한 골세포 분화 방법에 관한 것으로서, 보다 상세하게는 옥추출물에 의해 활성화된 피부세포의 분비물을 이용한 줄기세포의 골세포 분화 방법에 관한 것이다.The present invention relates to a method for differentiating bone cells using a jade extract, and more particularly, to a method for differentiating bone cells of stem cells using a secretion product of skin cells activated by the jade extract.

옥(비취, Jade)은 스페인이 중남미를 정복했을 때, 신장병을 예방하거나 치료해 주는 보석이라는 의미의 piedra de ijada에서 유래되었다.Jade is derived from piedra de ijada, meaning a jewel that prevents or cures kidney disease when Spain conquered Latin America.

옥은 예로부터 천지의 정수로서 몸에 지니고 있으면 약효가 있고 잡귀를 물리칠 수 있는 것으로 여겨지고 있다. 또한, 옥은 신체 장식이나 의복 장식의 기본적인 재료로서 사용되고 있다. 옥은 원석을 갈고 다듬어 작은 원형으로 만든 후 구멍을 뚫어서 사용되는 것이 일반적인데, 목걸이, 반지 및 팔찌 등과 같은 다양한 형태로 사용되고 있다. 예로부터 사용된 옥의 종류로는 마노, 유리, 호박, 석웅황, 비취, 천하석옥, 황옥 등이 있다.Jade is the essence of the heavens and the earth from ancient times, and it is believed to have medicinal properties and to defeat mischief if it is worn in the body. Also, jade is used as a basic material for body decoration and clothing decoration. Jade is commonly used by grinding and trimming gemstones into small circles and then punching holes. It is used in various forms such as necklaces, rings and bracelets. The types of jade used since ancient times include agate, glass, amber, seokwoonghwang, jade, cheonhaseokok, and topaz.

옥은 경옥(硬玉)과 연옥(軟玉)으로 구분된다. 경옥은 휘석족(煇石族, pyroxene family)에 속하는 납 휘석조 광물로서, 규산 및 소다(soda)로 구성된 단사정계(單斜晶系) 물질이고, 그 경도는 수정과 같은 치밀한 덩어리이며, 빛은 흑색, 청록, 녹색이고, 반투명한 성질을 갖는다. 연옥(Nephrite Jade)은 이노규산염(Inosilicates)의 단사정계 휘섬석(煇閃石) 광물체로 고토질 대리암 중 사문석화 초염기성 연옥(蛇紋石化超鹽氣性 軟玉)으로 나뉘어진다. 연옥의 품질은 미세한 구조 즉, 투각섬석-양기석 정자가 속조(束組)와 섬유로 되는 조세(粗細)한 정도로 결정되며, 섬유가 극히 가늘수록 품질이 좋은 것으로 알려져 있다.Jade is divided into jadeite (硬玉) and purgatory (軟玉). Jadeite is a lead pyroxene mineral belonging to the pyroxene family, and is a monoclinic material composed of silicic acid and soda, and its hardness is a dense mass like crystal and light. Is black, cyan, green, and has translucent properties. Nephrite Jade is a monoclinic fissile mineral of Inosilicates, and is divided into serpentine superbasic purgatory among the paleo-soil marbles. The quality of purgatory is determined by the finer structure, that is, the fine structure of openwork-yanggiseok sperm, which is made up of sockjo (束組) and fibers, and it is known that the finer the fiber is, the better the quality.

한편, 현대 성인병의 90%는 불포화 지방산이 산화할 때 발생하는 과산화 지질이 혈액 순환계통에 장애를 일으킬 때 발생하는데, 우리 인체에는 과산화 지질을 제거하는 SOD(Glutathione Peroxidase, GSH-PX)라는 효소가 존재하여 건강을 유지하게 된다. 그러나 성인이 되면서 이러한 효소들의 유도능력(Induction Capacity)이 저하되어 신체 내의 과산화 지질이 혈관벽 등에 침착되면서 서서히 성인병이 되는 것으로 밝혀지고 있다.On the other hand, 90% of modern adult diseases are caused when lipid peroxide, which occurs when unsaturated fatty acids are oxidized, causes disorders in the blood circulation system.In our human body, an enzyme called SOD (Glutathione Peroxidase, GSH-PX) that removes lipid peroxidation It exists and stays healthy. However, as adults become older, the induction capacity of these enzymes decreases, and as lipid peroxide in the body is deposited on the walls of blood vessels, it has been found to gradually become adult diseases.

옥은 광석 자체에서 생육 광선인 5-20㎛의 원적외선을 다량으로 방출하는 성질을 갖는다. 이러한 흡수광의 원적외선은 신체 내의 불포화지방산, 과산화지질, 오염된 물 등의 중합 고리에 강력하게 작용한다. 옥에서 방출되는 원적외선에 의해 이들 오염 성분들의 이중, 삼중의 결합이 분리되므로 인체의 생리 활성 작용이 증대되고 촉진된다.Jade has the property of emitting a large amount of far-infrared rays of 5-20㎛, which is a growing ray from the ore itself. The far-infrared rays of the absorbed light act strongly on the polymerized rings of unsaturated fatty acids, lipid peroxides, and contaminated water in the body. Since the double and triple bonds of these contaminants are separated by far-infrared rays emitted from the jade, the physiological activity of the human body is increased and promoted.

독일의 권위 있는 의학계 문헌(Mauda Palmer Die Verborgene의 KRAFF der KRISTALLE und der EDELSTEINE)에 발표된 보고에 의하면, 경옥과 연옥은 서로 다른 두 가지의 상이한 광석으로서 이들은 대부분의 보석처럼 실리콘과 산소를 함유하고 있다. 그러나 경옥은 과립형 크리스탈로 형성되어 있는데 반해, 연옥은 섬유질, 머리털과 같은 무수한 크리스탈과 미립 집합체로 이루어져 있다는 점에서 차이가 있다. 특히, 경옥은 인체에 유익한 3가지 성분 즉, 칼슘, 철분, 마그네슘을 주성분으로 하고 있기 때문에, 고혈압, 당뇨병 순환기 장애, 심장병 및 신장 장애로 인한 병의 치유에 커다란 영향을 미치는 것으로 보고된 바 있다.According to a report published in the prestigious German medical literature (KRAFF der KRISTALLE und der EDELSTEINE by Mauda Palmer Die Verborgene), jadeite and purgatory are two different ores that contain silicon and oxygen like most gemstones. . However, while jadeite is formed of granular crystals, purgatory differs in that it is composed of countless crystals such as fibers and hair and fine grain aggregates. In particular, jadeite has been reported to have a great effect on the healing of diseases caused by high blood pressure, diabetic circulatory disorders, heart disease, and kidney disorders, since jadeite is mainly composed of three components beneficial to the human body, namely calcium, iron, and magnesium.

그러나 옥은 그 희소성으로 인하여 상기와 같은 탁월한 의학적 효능이 있는 것으로 알려져 있음에도, 대부분 목걸이, 반지, 팔찌 등의 일부 신변장식용 보석 장신구로만 한정적으로 이용되고 있다. 또한, 옥은 고가품이기 때문에 옥을 이용한 일반 생활용품으로의 개발은 상대적으로 미약한 실정이다. 따라서 옥을 일상 생활에서 다양하게 이용할 수 있도록 옥에 대한 연구 개발이 필요하다.However, although jade is known to have excellent medical effects as described above due to its rarity, it is mostly used only as a jewelry accessory for personal decoration such as necklaces, rings, and bracelets. Also, since jade is a high-priced product, the development of jade as a general household product is relatively weak. Therefore, it is necessary to research and develop jade so that jade can be used in various ways in everyday life.

한편, 골수 유래 성체 줄기세포가 골형성 세포로 분화되는 것이 확인되었고(Friedenstein A.J. et al., Transplantation., 6:230-247, 1968), 골수로부터 분리한 줄기세포를 배양하여 골아세포로 분화 증식시키는 방법에 진전이 있으며 이를 통한 임상적용의 가능성이 높아지고 있다(Ohgushi H. et al., J. Biomed Mater Res., 48:913-927, 1999). 따라서, 줄기세포로부터 골세포를 분화시키는 방법이 주도적으로 연구되고 있는 실정이다.Meanwhile, it was confirmed that bone marrow-derived adult stem cells differentiate into osteogenic cells (Friedenstein AJ et al., Transplantation., 6:230-247, 1968), and stem cells isolated from bone marrow are cultured to differentiate into osteoblasts and proliferate. There is progress in the treatment method, and the possibility of clinical application through it is increasing (Ohgushi H. et al., J. Biomed Mater Res., 48:913-927, 1999). Therefore, a method of differentiating bone cells from stem cells is being actively studied.

조직공학 중에서도 생체에서 완전히 흡수되고 세포와 친화력이 있는 고분자 담체를 생체 조직에 이식함으로써 새로운 실질 조직을 형성하게 하는 일련의 기법을 생체조직공학이라고 한다. 생체 조직공학은 세포 배양학, 재료공학, 이식수술 분야의 다학제간 조합이다. 이와 같은 생체 조직공학은 오늘날 다방면으로 연구되어 인체의 특정부위에 손상을 입은 환자의 치료에 유용하게 활용되고 있다.Among tissue engineering, a series of techniques that allow the formation of new parenchymal tissues by implanting a polymer carrier that is completely absorbed by the living body and has affinity with cells is called bio-tissue engineering. Biotissue engineering is a multidisciplinary combination of cell culture, material engineering, and transplant surgery. Such biological tissue engineering has been studied in various fields today, and is being used to treat patients who have been damaged in a specific part of the human body.

최근에는 환자의 자가세포로부터 줄기세포를 채취하여, 손상된 조직으로 재생하는 조직공학적 치료방법이 각광을 받고 있다. 환자의 자가세포로부터 채취한 줄기세포를 배양하고 특정조직으로 분화를 유도하여 이를 환자의 결손부 조직에 이식할 경우, 이식거부반응이 없어 유용하다. 사람간의 최초의 성공적인 장기 이식은 1954년 조셉 머레이(Josep Murray)에 의하여 시도된 일란성 쌍생아 형제간의 신장이식이었다. 그 후 많은 발전을 거듭한 끝에 사람의 장기 이식은 1970년대 후반부터는 새로운 면역 억제제의 개발과 마취 및 수술 기법의 발달로 심장, 간, 췌장 및 폐 등의 인간 장기 모든 분야에까지 확대되고 있는 실정이다.Recently, a histo-engineered treatment method in which stem cells are collected from autologous cells of a patient and regenerated into damaged tissues is in the spotlight. In the case of culturing stem cells collected from the patient's autologous cells and inducing differentiation into specific tissues and transplanting them into the defective tissue of the patient, it is useful because there is no transplant rejection reaction. The first successful organ transplant between humans was a kidney transplant between identical twin siblings, attempted by Joseph Murray in 1954. After many developments since then, human organ transplantation is expanding to all areas of human organs such as the heart, liver, pancreas, and lungs from the late 1970s with the development of new immunosuppressants and anesthesia and surgical techniques.

이러한 이식수술의 발전은 인류의 건강 증진에 매우 중요한 역할을 하였으나 점차 필요로 하는 장기의 수보다 기증되는 장기의 수가 현저히 부족하게 되어 한계에 다다랐고, 이러한 문제점을 해결하고자 동물의 장기를 사람에게 이식하는 소위 이종 이식을 연구하여 보기도 하였으나 오랜 시간 사용시 거부반응과 감염 등의 문제가 발생하여 자주 교환하여 주어야 하고, 거부반응이나 감염 등의 문제가 없다 하더라도 기능상으로 생명을 유지하기에는 현저히 뒤떨어지는 문제가 있었다.The development of transplantation surgery played a very important role in promoting human health, but the number of donated organs gradually became significantly less than the number of organs needed, reaching the limit. To solve this problem, organs from animals were transplanted to humans. I have studied and looked at so-called xenotransplantation, but when used for a long period of time, problems such as rejection and infection occur and must be exchanged frequently, and even if there are no problems such as rejection or infection, there is a problem that is significantly inferior in functioning to maintain life. there was.

이러한 문제점을 해결하고자 인체 내에 거부 반응이 전혀 없는 생체 적합성이 뛰어난 생체 재료를 개발하거나 환자 자신의 세포로부터 손상된 장기를 대체하려는 생체 조직 공학적인 접근 방법이 연구되고 있다.In order to solve this problem, biomaterials with excellent biocompatibility without rejection in the human body have been developed, or bio-tissue engineering approaches have been studied to replace damaged organs from the patient's own cells.

먼저 생체 적합성이 뛰어난 인공 생체 재료에는 인체 내에서 존재하거나 자연에서 얻을 수 있는 천연 재료가 있고 각종 폴리머로 대표되는 인공 재료가 있다. 천연 재료에는 키틴이나 키토산 등이 있고 인공재료에는 폴리우레탄과 실리콘 고무 등의 합성 고분자가 있는데 이들 재료는 물리 화학적 표면 성질 또는 기계적 성질을 다양하게 변화시킬 수 있다는 장점이 있으나 시간이 흐름에 따라 혈액 등의 응고가 일어나 영구적으로 인체내에서 사용할 수 없다는 단점을 지니고 있다. 따라서 이를 보완하기 위하여 환자 자신의 세포로부터 손상된 장기를 대체하려는 생체 조직 공학적인 방법이 많이 연구되고 있다.First, artificial biomaterials with excellent biocompatibility include natural materials that exist in the human body or can be obtained from nature, and artificial materials represented by various polymers. Natural materials include chitin and chitosan, and artificial materials include synthetic polymers such as polyurethane and silicone rubber. These materials have the advantage of being able to change physicochemical surface properties or mechanical properties in various ways. It has the disadvantage that it cannot be used permanently in the human body due to coagulation of Therefore, in order to compensate for this, many studies have been conducted on bio-tissue engineering methods to replace damaged organs from the patient's own cells.

골이식술의 가장 이상적인 치유양상은 이식재의 완전한 숙주골화다. 그러나 이식재의 기원이나 처리과정에 따라 골의 치유 양상이 다른 것으로 알려져 있다. 이러한 이유로 조직 재생과정에서 생체 내 이식 후 특정 조직 및 장기 특이적으로 분화할 수 있는 능력이 있고, 또한 본래 세포 특성과 다르게 타 조직의 세포로 전이 분화할 수 있는 성체 줄기세포의 이용에 관심이 모아지고 있다.The ideal healing modality of bone grafts is complete host ossification of the graft material. However, it is known that bone healing patterns differ depending on the origin and treatment process of the graft material. For this reason, interest in the use of adult stem cells that have the ability to differentiate specifically to specific tissues and organs after in vivo transplantation in the process of tissue regeneration, and that can metastasize to cells of other tissues differently from the original cell characteristics, has attracted attention. Is losing.

줄기세포(Stem cell)는 인간의 몸을 구성하는 서로 다른 세포나 장기가 성장하는 일종의 모세포로, 간세포라 불리기도 한다. 줄기세포에는 사람의 배아를 이용해 만들 수 있는 배아줄기세포(Embryonic stem cell)와 혈구세포를 끊임없이 만드는 골수세포와 같은 성체 줄기세포(Adult stem cell)가 있다. 배아줄기세포는 인체를 이루는 모든 세포와 조직으로 분화할 수 있지만 윤리적인 이유로 사용이 제한되어 있는 반면, 성체 줄기세포는 제대혈이나 다 자란 성인의 골수와 혈액 등에서 추출한 것으로, 간엽 줄기세포와 조혈 줄기세포로 존재한다. 성체 줄기세포는 생체 내 이식 후에 특정 조직 및 장기 특이적으로 분화할 수 있고, 본래 세포의 특성과는 다른 타 조직의 세포로 전이 분화할 수 있는 분화 유연성을 가지는 세포로서, 윤리적인 제한 없어 조직공학에 널리 사용되고 있다.Stem cells are a type of parent cell in which different cells or organs that make up the human body grow, and are also called stem cells. Stem cells include embryonic stem cells, which can be made using human embryos, and adult stem cells, such as bone marrow cells that constantly make blood cells. Embryonic stem cells can differentiate into all cells and tissues that make up the human body, but their use is limited for ethical reasons, whereas adult stem cells are derived from umbilical cord blood or bone marrow and blood of mature adults, and are mesenchymal stem cells and hematopoietic stem cells. Exists as. Adult stem cells are cells with differentiation flexibility that can differentiate specifically to specific tissues and organs after transplantation in vivo and can metastasize into cells of other tissues different from the original cell characteristics. Is widely used in

이미 인간과 동물을 대상으로 한 연구에서 성체 줄기세포 중 골수 유래 줄기세포가 골형성 세포로 분화되는 것이 확인되었고(Friedenstein A.J. et al., Transplantation., 6:230-247, 1968), 최근 연구에서는 골수로부터 분리한 줄기세포를 배양하여 골아세포로 분화 증식시키는 방법에 진전이 있으며 이를 통한 임상적용의 가능성이 높아지고 있다(Ohgushi H. et al., J Biomed Mater Res., 48:913-927, 1999). 최근에는 간엽줄기세포로부터 골세포를 분화시키는 방법이 주도적으로 연구되고 있는 실정이다.Already in human and animal studies, it has been confirmed that bone marrow-derived stem cells among adult stem cells are differentiated into osteogenic cells (Friedenstein AJ et al., Transplantation., 6:230-247, 1968). There is progress in the method of culturing stem cells isolated from bone marrow to differentiate and proliferate into osteoblasts, and the possibility of clinical application through this is increasing (Ohgushi H. et al., J Biomed Mater Res., 48:913-927, 1999 ). In recent years, a method of differentiating bone cells from mesenchymal stem cells is being actively studied.

그러나, 자가 골이식은 기본적인 신체의 체력 및 면역력이 저하된 환자로부터 골채취를 하여야 하는바 골채취 부위의 감염, 동통, 혈종과 같은 합병증이 발생할 수 있는 문제점이 있었고, 이를 극복하기 위해 이식거부반응이 없는 공여자로부터 골채취를 하는 것을 고려한다 하더라도 이러한 골수 공여자의 수는 제한적일 수밖에 없는 문제점이 존재한다. 따라서 환자의 다른 신체부위로부터 취한 줄기세포를 골세포로 분화시키기는 방법의 개발이 절실히 요구되어 왔다.However, autologous bone graft requires bone harvesting from patients with reduced basic physical strength and immunity.There are problems that may result in complications such as infection, pain, and hematoma at the bone collection site. Even if it is considered to collect bones from a donor who does not have a bone marrow, there is a problem that the number of bone marrow donors is limited. Therefore, there has been an urgent need to develop a method for differentiating stem cells taken from other body parts of patients into bone cells.

이에, 본 발명자들은 줄기세포로부터 골세포를 분화유도하는 방법을 개발하고자 노력하고, 특히 옥 추출물의 골분화촉진기능의 가능성을 주목하고 그 실제 효과를 검증하기 위한 다양한 방안을 강구하던 중, 옥 추출물을 먼저 피부세포에 처리하고 그 추출물 자극으로 인해 분비된 피부세포의 기능성 성분이 포함된 배지 상층액을 얻어 지방유래줄기세포(ADSC)에 처리한 결과 ADSC의 골분화를 유전자 발현등을 분석함으로써 그 조성물이 골세포 분화를 유도할 수 있음을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors are striving to develop a method for inducing the differentiation of bone cells from stem cells, and in particular, while paying attention to the possibility of the bone differentiation promoting function of the jade extract and devising various methods to verify its actual effect, jade extract Was first treated on skin cells, and the supernatant of the medium containing the functional ingredients of the skin cells secreted by stimulation of the extract was obtained and treated with adipose-derived stem cells (ADSC). As a result, bone differentiation of ADSC was analyzed by analyzing gene expression. The present invention was completed by confirming that the composition can induce bone cell differentiation.

본 발명의 목적은 포유동물의 피부유래 성분으로부터 줄기세포를 골세포로 분화시킬 수 있는 방법을 제공하는 것이다.An object of the present invention is to provide a method for differentiating stem cells into bone cells from components derived from the skin of a mammal.

본 발명의 목적은 옥 추출물을 피부세포에 처리하여 활성화된 피부세포의 기능성 분비물이 포함된 배지 상층액을 얻어 이것을 지방유래줄기세포에 처리한 후 골 유전자를 발현을 분석함으로써 골분화촉진 기능을 확인하고, 상기 얻어진 골세포를 이용한 치료 및 화장료용 조성물을 제공하는 것이다.The object of the present invention is to obtain a medium supernatant containing functional secretions of activated skin cells by treating the jade extract on skin cells, and then to treat this on adipose-derived stem cells and analyze the expression of bone genes to confirm the function of promoting bone differentiation. And, to provide a composition for treatment and cosmetics using the obtained bone cells.

상기 목적을 달성하기 위하여, 본 발명은 1) 옥 추출물을 피부세포(Fibroblast)에 처리하여 활성화된 기능성 성분을 배출시키는 단계; 2) 상기 기능성 성분이 포함된 배지의 상층액을 분리하는 단계; 3) 상기 분리된 배지 상층액을 줄기세포에 처리하여 배양하여 골세포로 분화시키는 단계; 및 3) 상기 분화된 골세포를 분리하는 단계;를 포함하는 옥추출물에 의한 줄기세포의 골세포 분화 방법을 제공한다.In order to achieve the above object, the present invention comprises the steps of: 1) treating the jade extract to skin cells (Fibroblast) to discharge the activated functional ingredients; 2) separating the supernatant of the medium containing the functional ingredient; 3) treating and culturing the separated medium supernatant on stem cells to differentiate into bone cells; And 3) separating the differentiated bone cells. It provides a method for differentiating bone cells of stem cells using the jade extract.

또한, 본 발명은 상기 방법에 의해 제조된 골세포가 함유된 피부세포 복원 또는 관절염 치료용 조성물과 상기 방법에 의해 제조된 골세포가 함유된 기능성 화장료 조성물을 제공한다.In addition, the present invention provides a composition for restoring skin cells or treating arthritis containing bone cells prepared by the method and a functional cosmetic composition containing bone cells prepared by the method.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 1) 옥 추출물을 피부세포(Fibroblast)에 처리하여 활성화된 기능성 성분을 배출시키는 단계; 2) 상기 기능성 성분이 포함된 배지의 상층액을 분리하는 단계; 3) 상기 분리된 배지 상층액을 줄기세포에 처리하여 배양하여 골세포로 분화시키는 단계; 및 3) 상기 분화된 골세포를 분리하는 단계;를 포함하는 옥추출물에 의한 줄기세포의 골세포 분화 방법을 제공한다.The present invention comprises the steps of: 1) treating the jade extract to skin cells (Fibroblast) to discharge the activated functional ingredients; 2) separating the supernatant of the medium containing the functional ingredient; 3) treating the separated medium supernatant to stem cells and culturing them to differentiate into bone cells; And 3) separating the differentiated bone cells. It provides a method for differentiating bone cells of stem cells using a jade extract.

본 발명의 옥추출물에 의한 줄기세포의 골세포 분화 방법에 있어서, 상기 옥 추출물은 옥을 70℃에서 2시간 동안 열수 추출하고 50~500 ug/mL 농도로 감압농축하는 것이 바람직하고, 상기 줄기세포는 지방유래 줄기세포(ADSC)인 것이 바람직하며, 상기 3) 단계의 배양은 1~10일 동안 이루어지는 것이 바람직하다.In the method for differentiation of stem cells from stem cells by the jade extract of the present invention, the jade extract is preferably extracted with hot water at 70° C. for 2 hours and concentrated under reduced pressure at a concentration of 50 to 500 ug/mL, and the stem cells Is preferably an adipose-derived stem cell (ADSC), and the culture in step 3) is preferably performed for 1 to 10 days.

본 발명은 옥추출물에 의해 활성화된 피부세포의 분비물이 지방유래 줄기세포를 골세포로 분화시키는 활성이 있음에 기초한 옥 추출물의 골분화촉진기능에 관한 것이다. 구체적으로, 옥 추출물의 골분화촉진을 위하여, 옥 추출물을 피부세포에 처리한 후 추출물 자극으로 인해 분비된 피부세포의 기능성 성분이 포함된 배지 상층액을 얻어 지방유래줄기세포(ADSC)에 처리한 후 ADSC의 골분화를 유도함을 유전자 증폭 및 발현 분석등으로 확인하였다.The present invention relates to a function of promoting bone differentiation of a jade extract based on the fact that the secretion of skin cells activated by the jade extract has an activity of differentiating adipose-derived stem cells into bone cells. Specifically, in order to promote bone differentiation of the jade extract, after treating the skin cells with the jade extract, a medium supernatant containing the functional ingredients of the skin cells secreted due to the extract stimulation was obtained and treated with adipose-derived stem cells (ADSC). After that, it was confirmed by gene amplification and expression analysis that it induces bone differentiation of ADSC.

또한, 본 발명은 상기 방법에 의해 제조된 골세포가 함유된 피부세포 복원 또는 관절염 치료용 조성물과 상기 방법에 의해 제조된 골세포가 함유된 기능성 화장료 조성물을 제공한다.In addition, the present invention provides a composition for restoring skin cells or treating arthritis containing bone cells prepared by the method and a functional cosmetic composition containing bone cells prepared by the method.

본 발명의 화장료 조성물에 있어서, 상기 조성물은 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지 크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 영양에센스, 팩, 비누, 샴푸, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 유액, 프레스파우더, 루스파우더 및 아이섀도우로 이루어진 군으로부터 선택된 화장품에 사용되는 것이 바람직하고, 상기 조성물은 화장품학 또는 피부과학 분야에서 통상적으로 사용되며 일반적으로 사용되는 함량을 포함하는 보조제를 추가로 포함하는 것이 바람직하며, 이때 상기 보조제는 지방 물질, 유기 용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제 및 지질 소낭으로 이루어진 군으로부터 선택된 하나 이상을 포함하는 것이 보다 바람직하다.In the cosmetic composition of the present invention, the composition is skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, It is preferable to be used in cosmetics selected from the group consisting of packs, soaps, shampoos, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, emulsions, press powders, loose powders, and eye shadows, and the composition is cosmetology or skin It is preferable to further include an auxiliary agent that is commonly used in the scientific field and includes an amount generally used, wherein the auxiliary agent is a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, an emollient, an antioxidant, a suspending agent. , Stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments It is more preferable to include at least one selected from the group consisting of hydrophilic or lipophilic active agents and lipid vesicles.

또한 상기 기능성 화장료 조성물의 유효성분의 함유량은 사용형태, 사용목적, 사용방법, 제제형 등에 따라 다르나, 예컨대 화장제로서는 0.01 내지 8중량%, 바람직하기로는 0.5 내지 5중량% 함유되며, 연고제 또는 크림제로서는 0.01 내지 12중량%, 바람직하기로는 5 내지 12중량%이고, 나머지는 각 제제에 필요한 첨가제 및 용매 등으로 채워진다.In addition, the content of the active ingredient in the functional cosmetic composition varies depending on the type of use, purpose of use, method of use, formulation, etc., but, for example, 0.01 to 8% by weight, preferably 0.5 to 5% by weight of a cosmetic agent is contained, and an ointment or cream The agent is 0.01 to 12% by weight, preferably 5 to 12% by weight, and the remainder is filled with additives and solvents required for each formulation.

본 발명의 골세포가 함유된 기능성 화장료 조성물은 이외에 글리콜산과 비타민C 외에도, 연고기제 및 보습제, 연화제, 습윤제, 활택제, 보존제 등의 각종 첨가제를 포함할 수 있다.In addition to the functional cosmetic composition containing the bone cells of the present invention, in addition to glycolic acid and vitamin C, it may contain various additives such as a soft meat and a moisturizer, an emollient, a humectant, a lubricant, and a preservative.

상기 첨가제로는 경랍, 스테아릴알콜, 폴리에틸렌글리콜 4000, 글리세린, 세탄올, 라우릴황산나트륨, 파라옥시안식향산에틸, 파라옥시안식향산부틸 및 프로필렌글리콜 등이 포함되며, 이러한 첨가제는 각각 첨가하거나 또는 상업적으로 구입가능한 기제에 포함되어 있는 성분의 형태로 첨가될 수 있다.The additives include spermaceti, stearyl alcohol, polyethylene glycol 4000, glycerin, cetanol, sodium lauryl sulfate, ethyl paraoxybenzoate, butyl paraoxybenzoate, and propylene glycol, and these additives are added respectively or purchased commercially. It can be added in the form of ingredients contained in the possible base.

경랍(sperm wax)은 고래의 두부에 있는 납질의 고형성분을 정제하여 얻은 것으로 다른 기제에 첨가되어 연고에 적당한 조도를 부여하며 적정량 첨가될 수 있다. 스테아릴알콜(stearyl alcohol)은 활택제로서 작용하며 적정량 첨가될 수 있다. 폴리에틸렌글리콜 4000은 대표적인 수용성 기제로서 산화에틸렌과 물과의 중합체이며 물에 잘 녹고 대부분의 의약품과의 혼합성이 좋고 주약의 흡수가 우수한 것으로 적정량 사용될 수 있다.Sperm wax is obtained by refining the waxy solid component in the tofu of whales. It is added to other bases to give the ointment an appropriate consistency and can be added in an appropriate amount. Stearyl alcohol (stearyl alcohol) acts as a lubricant and can be added in an appropriate amount. Polyethylene glycol 4000 is a representative water-soluble base, a polymer of ethylene oxide and water. It is well soluble in water, has good mixing properties with most pharmaceuticals, and has excellent absorption of the main drug. It can be used in an appropriate amount.

글리세린은 연화제 및 흡습제로서 적정량 사용될 수 있다. 세탄올은 유화제 및 증점제로서 적정량 사용될 수 있다. 라우릴황산나트륨(sodium lauryl sulfate)은 조성물의 혼합을 돕기위한 습윤연화제로서 적정량 사용될 수 있다. 파라옥시안식향산에틸 및 파라옥시안식향산부틸은 제제의 유효성을 지속시키는 보존제로서 유효량 포함될 수 있다. 상기 보존제들은 넓은 pH 영역에서 활성을 보이며 2종류의 병용에 의해 유효성이 증대된다. 프로필렌글리콜은 계면활성제로서 5 내지 10중량% 사용될 수 있으며,글리콜산과 비타민 C의 피부 흡수를 도와준다.Glycerin can be used in an appropriate amount as an emollient and a desiccant. Cetanol may be used in an appropriate amount as an emulsifier and thickener. Sodium lauryl sulfate (sodium lauryl sulfate) may be used in an appropriate amount as a wetting emollient to aid in mixing the composition. Ethyl paraoxybenzoate and butyl paraoxybenzoate may be included in an effective amount as a preservative for sustaining the effectiveness of the formulation. The preservatives exhibit activity in a wide pH range, and their effectiveness is increased by using the two types together. Propylene glycol may be used in an amount of 5 to 10% by weight as a surfactant, and it helps the skin absorption of glycolic acid and vitamin C.

본 발명의 골세포 분화방법을 사용할 경우 지방유래 줄기세포를 골세포로 분화시킬 수 있다. 따라서, 본 발명에 따른 골세포분화 촉진은 옥추출물의 성장기 유아의 골발육과 중장년의 골다공증 예방 등에 효과적으로 사용될 수 있으며, 본 발명에 따라 얻어진 골세포는 일반 흉터, 화상 흉터와 같은 피부질환과 골 결손부 시술 등의 골대사성 질환 등의 치료에 유용하게 사용될 수 있다.When the bone cell differentiation method of the present invention is used, adipose-derived stem cells can be differentiated into bone cells. Therefore, the promotion of bone cell differentiation according to the present invention can be effectively used for the prevention of osteoporosis in the middle and old age and bone development of the growing infant of the jade extract, and the bone cells obtained according to the present invention can be used for skin diseases such as general scars and burn scars and bone defects. It can be usefully used in the treatment of bone metabolic diseases such as minor procedures.

도 1은 본 발명의 전체적 실험과정을 개괄적으로 도식한 표이다.
도 2 및 도 3은 피부세포의 옥 추출물 세포독성 실험으로 옥 추출물하에서 피부세포의 유세포분석 그래프(도 2)와 세포 활성도(도 3)를 나타낸 그래프이다.
도 4 내지 도 6은 옥 추출물에 의한 골세포 분화 유전자의 발현을 나타낸 것이다.
도 7은 활성화된 피부세포에 의한 골세포 분화를 나타낸 것이다.
도 8은 본 발명에 사용된 옥 분말에 존재하는 생균수를 나타낸 시험성적서이다.
도 9는 본 발명의 추출물의 성분 분석 시험성적서이다.
도 10은 세포 형태 변화를 나타낸 그래프이다.
도 11 및 도 12는 세포 형태 변화의 저배율(도 11)과 고배율(도 12) 사진이다.
도 13은 옥 분말의 세포독성실험을 나타낸 그래프이다.
도 14는 세포 내 칼슘이온 농도 변화를 나타낸 그래프이다.
1 is a table schematically showing the overall experimental process of the present invention.
2 and 3 are graphs showing flow cytometry graphs (FIG. 2) and cell activity (FIG. 3) of skin cells under the jade extract as a cytotoxicity experiment for jade extract of skin cells.
4 to 6 show the expression of bone cell differentiation genes by the jade extract.
7 shows the differentiation of bone cells by activated skin cells.
8 is a test report showing the number of viable cells present in the jade powder used in the present invention.
9 is a component analysis test report of the extract of the present invention.
10 is a graph showing changes in cell morphology.
11 and 12 are photographs of low magnification (FIG. 11) and high magnification (FIG. 12) of cell morphology change.
13 is a graph showing the cytotoxicity experiment of jade powder.
14 is a graph showing changes in the concentration of calcium ions in cells.

이하, 본 발명을 설명한다.Hereinafter, the present invention will be described.

먼저 옥가루를 열수 추출 및 감압농축으로 농축하여 다양한 농도의 옥 추출물을 제조하였다. 또한, 피부세포(Fibroblast)를 배양하고, 상기 옥 추출물을 다양한 농도로 상기 배양된 피부세포에 처리함으로써 최적으로 처리할 옥 추출물 농도를 결정하였다.First, jade powder was extracted with hot water and concentrated under reduced pressure to prepare jade extracts of various concentrations. In addition, skin cells (Fibroblast) were cultured, and the jade extract concentration to be optimally treated was determined by treating the cultured skin cells with the jade extract at various concentrations.

상기 옥 추출물이 처리된 피부세포의 배양액의 상등액을 분리하고 이것을 미리 배양된 지방유래 줄기세포(ADSC)에 처리하고 1~10일 동안 각각 세포에 대한 골세포 분화여부를 분석하였다.The supernatant of the culture medium of the skin cells treated with the jade extract was separated, treated with pre-cultured adipose-derived stem cells (ADSC), and analyzed for bone cell differentiation for each cell for 1 to 10 days.

그 결과, 7일 배양한 세포에서 다양한 골분화 마커, 골분화 유전자를 발현함을 확인하였다. 즉, 옥추출물에 의해 활성화된 피부세포가 골 분화 촉진 물질을 분비하였으며 이로 인해 ADSC의 골 분화가 촉진된다.As a result, it was confirmed that various bone differentiation markers and bone differentiation genes were expressed in cells cultured for 7 days. In other words, skin cells activated by the jade extract secrete a substance that promotes bone differentiation, which promotes bone differentiation of ADSC.

이하, 본 발명에 따른 바람직한 실시예를 더욱 구체적으로 제시하여 상세하게 설명하기로 한다. 그러나, 이하의 실시예는 이 기술분야에서 통상적인 지식을 가진 자에게 본 발명이 충분히 이해되도록 제공되는 것으로서 여러 가지 다른 형태로 변형될 수 있으며, 상기와 같은 실시예들에 의하여 본 발명이 한정되는 것은 아니다. Hereinafter, preferred embodiments according to the present invention will be described in more detail by presenting them in more detail. However, the following embodiments are provided so that the present invention may be sufficiently understood by those of ordinary skill in the art, and may be modified in various other forms, and the present invention is limited by the above embodiments. It is not.

<실시예 1> 옥 추출물의 피부세포 처리 농도 결정<Example 1> Determination of skin cell treatment concentration of jade extract

먼저, 피부세포(Fibroblast)(한국세포주은행)를 배양배지(DMEM, Hyclone)에서 옥 추출물을 처리하고 37℃, 5% CO2에서 세포밀도 80%까지 배양하였다.First, skin cells (Fibroblast) (Korea Cell Line Bank) were treated with jade extract in culture medium (DMEM, Hyclone), and cultured to 80% cell density at 37°C and 5% CO2.

옥 추출물은 옥가루를 열수 추출 (70℃, 2시간) 및 감압농축기(WEV-1001V, 대한과학)로 농축하여 사용하였으며 각각의 옥 추출물 농도 (50, 100, 300, 500 ug/mL)를 상기 피부세포에 24시간 동안 처리한 후 세포 생존율을 측정(Annexin V FITC and PI, Invitrogen)하였다(도 3). 세포 생존율 분석은 유세포분석기(Calbuir, BD science) 및 분석프로그램(FlowJo 10.6, BD science)으로 실행하였다(도 2).The jade extract was used by extracting jade powder with hot water (70° C., 2 hours) and a vacuum concentrator (WEV-1001V, Korea Science), and the concentration of each jade extract (50, 100, 300, 500 ug/mL) was applied to the skin. After the cells were treated for 24 hours, cell viability was measured (Annexin V FITC and PI, Invitrogen) (FIG. 3). Cell viability analysis was performed with a flow cytometer (Calbuir, BD science) and an analysis program (FlowJo 10.6, BD science) (FIG. 2).

상기 피부세포의 옥 추출물에 대한 세포생존율을 측정한 결과, 피부세포에 처리할 최적 농도는 150 ug/mL로 결정되었다.As a result of measuring the cell viability for the jade extract of the skin cells, the optimal concentration to be treated on the skin cells was determined to be 150 ug/mL.

<실시예 2> 옥 추출물의 피부세포 처리 배지 상등액의 분리<Example 2> Separation of the supernatant of skin cell treatment medium of jade extract

상기 실시예 1의 결과로 피부세포에 옥 추출물 150 ug/mL을 처리하여 옥 추출물이 처리된 섬유아세포의 상등액을 1ml 마이크로 파이펫으로 배지 상등액을 분리하였다.As a result of Example 1, the skin cells were treated with 150 ug/mL of the jade extract, and the supernatant of the fibroblasts treated with the jade extract was separated with a 1 ml micropipette.

<실시예 3> 지방유래줄기세포(ADSC)의 배양 및 피부세포 상등액 처리<Example 3> Culture of adipose-derived stem cells (ADSC) and treatment of skin cell supernatant

ADSC(StemPro™ Human Adipose-Derived Stem Cells, Thermofisher)를 배양배지(StemPro™ MSC SFM XenoFree, Gibco)에 37℃, 5% CO2에서 세포밀도 80%까지 배양하였다. 상기 실시예 2에서 얻어진 옥추출물 (150ug/mL)이 처리된 피부세포의 배양액의 상등액 100uL를 취하여 ADSC에 처리하고 1-10일까지 배양 후 각각의 세포를 취하여 하기와 같이 골분화 분석을 실시하였다. ADSC (StemPro™ Human Adipose-Derived Stem Cells, Thermofisher) was cultured in a culture medium (StemPro™ MSC SFM XenoFree, Gibco) at 37°C and 5% CO2 to 80% cell density. 100uL of the supernatant of the skin cell culture medium treated with the jade extract (150ug/mL) obtained in Example 2 was taken, treated with ADSC, and cultured for 1-10 days, and then each cell was taken and analyzed for bone differentiation as follows. .

<실시예 4> 지방유래줄기세포(ADSC)의 골분화분석<Example 4> Analysis of bone differentiation of adipose-derived stem cells (ADSC)

ADSC의 골분화 분석은 골분화 마커인 osteoponin(osteoponin-PE, biotechne), osteocalcin(osteocalcin-FITC, biotechne), sclerotin(SOST-Alexa647, Novusbio)의 항체를 이용하였고 이를 유세포분석기(Calbuir, BD science)및 분석프로그램(FlowJo 10.6, BD science)으로 분석하였다. 또한 골분화유전자인 Runx2, DLx5유전자의 발현을 PCR로 분석하였다. PCR분석에서 모든 RNA는 Ribospin reagent(GeneAll, Seoul, Korea)를 이용하여 추출하였다. cDNA 합성은 Maxime™ RT-Premix (iNtRON, Seong-nam, Korea)를 사용하였고 제작한 PCR Primer(Bioneer, Deajeon, Korea)를 이용하여 유전자 증폭(AccuPower PCR premix, Bioneer)을 실시하였다. 유전자 발현 분석은 케미닥(ibright FL1000, thermofisher)를 이용하여 분석하였다. 골분화 마커들에 상응하는 항체들로 염색한 후 형광현미경(Ts2-Nikon, Japan)을 이용하여 골세포의 유형 및 수를 카운트 하였다(도 4 내지 도 6). The bone differentiation analysis of ADSC was performed using antibodies of osteoponin (osteoponin-PE, biotechne), osteocalcin (osteocalcin-FITC, biotechne), and sclerotin (SOST-Alexa647, Novusbio), which are bone differentiation markers. And analysis program (FlowJo 10.6, BD science). In addition, the expression of the bone differentiation genes Runx2 and DLx5 genes was analyzed by PCR. In PCR analysis, all RNAs were extracted using Ribospin reagent (GeneAll, Seoul, Korea). For cDNA synthesis, Maxime™ RT-Premix (iNtRON, Seong-nam, Korea) was used, and gene amplification (AccuPower PCR premix, Bioneer) was performed using the prepared PCR Primer (Bioneer, Deajeon, Korea). Gene expression analysis was performed using Chemidak (ibright FL1000, thermofisher). After staining with antibodies corresponding to the bone differentiation markers, the type and number of bone cells were counted using a fluorescence microscope (Ts2-Nikon, Japan) (FIGS. 4 to 6 ).

골 분화 초기에 발현되는 유전자 Runx2와 Dlx5의 발현을 분석한 결과 7일간 배양한 세포에서 대조군 대비 Runx2발현 양은 4.19배 증가하였고 Dlx5의 발현 양은 1.24배 증가하였다. 이는 옥추출물에 의해 활성화된 피부세포가 골 분화 촉진 물질을 분비하였으며 이로 인해 ADSC의 골 분화가 촉진되었음을 확인할 수 있다. As a result of analyzing the expression of the genes Runx2 and Dlx5, which are expressed in the early stages of bone differentiation, the amount of Runx2 expression in cells cultured for 7 days increased by 4.19 times compared to the control, and the expression level of Dlx5 increased by 1.24 times. This can be confirmed that the skin cells activated by the jade extract secreted a substance that promotes bone differentiation, thereby promoting the bone differentiation of ADSC.

골 분화 세포에서 발현되는 osteocalcin과 osteoponin의 유세포분석 결과 3일 및 7일간 배양한 세포에서는 이 단백질들의 발현 양이 대조군 대비 1.7배 증가 하였으며 10일간 배양한 세포의 경우 2배 이상 증가하였다. 단백질수준에서 확인한 결과 PCR결과와 마찬가지로 옥 추출물에 의한 골분화가 촉진되었음을 확인할 수 있었다. As a result of flow cytometric analysis of osteocalcin and osteoponin expressed in osteogenic cells, the expression levels of these proteins increased by 1.7 times compared to the control in cells cultured for 3 days and 7 days, and more than doubled in cells cultured for 10 days. As a result of checking at the protein level, it was confirmed that bone differentiation was promoted by the jade extract, similar to the PCR result.

골 분화 세포를 형광 현미경으로 확인한 결과 osteoblast(골세포)는 3, 7, 10일에서 대조군 대비 최대 2배 증가하였으며 osteocyte(골세포)의 경우 3일차는 4,4배, 7일차는 10배, 10일차는 13배 증가하였다(도 7). 도 7은 활성화된 피부세포에 의한 골세포 분화를 나타낸 것이다.As a result of confirming bone differentiation cells with a fluorescence microscope, osteoblast (osteocyte) increased up to 2 times compared to the control on days 3, 7, and 10, and in the case of osteocyte (osteocyte), 4,4 times on day 3, 10 times on day 7, On the 10th day, it increased 13 times (Fig. 7). 7 shows the differentiation of bone cells by activated skin cells.

<실시예 5> 대식세포주를 이용한 옥가루의 면역반응 조절<Example 5> Control of immune response of jade powder using macrophage cell line

먼저 옥가루 0.1g을 10ml의 PBS에 희석한 후 원심분리하고, 상층액을 모아서 0.45uM 필터 통과 후 DMEM 배지에 희석하여 사용하였다. Raw246.7 세포주 (생쥐 대식세포)를 사용하여 각 그룹 당 최소 3회 이상 반복실험을 통하여 옥가루의 면역활성을 조사하였다. 처리한 LPS 농도는 6시간 시간 동안 20ng/ml을 처리하였다.First, 0.1 g of jade powder was diluted in 10 ml of PBS, centrifuged, and the supernatant was collected, passed through a 0.45 uM filter, and diluted in DMEM medium to be used. Using the Raw246.7 cell line (mouse macrophage), the immune activity of jade powder was investigated by repeating at least 3 times per group. The treated LPS concentration was treated with 20 ng/ml for 6 hours.

상기와 같이 LPS 단독 또는 옥가루와 함께 대식 세포에 처리하였다. 이때 LPS-pre Jade는 법제 전 옥가루이고 post Jade는 법제 후 옥가루이다.Macrophages were treated with LPS alone or with jade powder as described above. At this time, LPS-pre Jade is jade powder before legislation and post jade is jade powder after legislation.

칼슘 이온 농도는 1uM Calcium Green-1TM을 배양액에 희석 후 3시간 배양 후 형광 측정하였고, 세포독성실험은 Tryphan Blue exclusion test로 처리하였다. 통계처리는 student’t test와 one-way ANOVA를 이용하고, 통계적으로 P < 0.05인 값을 통계적으로 유의한 차이라고 간주하였다.Calcium ion concentration was measured by fluorescence after diluting 1uM Calcium Green-1 TM in the culture medium and incubating for 3 hours, and the cytotoxicity test was performed by Tryphan Blue exclusion test. For statistical processing, student't test and one-way ANOVA were used, and statistically, a value of P <0.05 was considered a statistically significant difference.

LPS 처리 후의 세포 형태 변화를 도 10에 나타었다. 그 결과, 각 그룹간의 통계적으로 유의미한 형태학적인 차이가 없었다. 이때, FSC-H (Forward sidescatter-Height)는 세포 크기 측정이고, SSC-H (Sidescatter-Height)는 세포 내 구조물 변화 측정이고, LPS-pre Jade는 법제 전 옥가루이고, post Jade는 법제 후 옥가루이다. 세포 형태 변화를 저배율(도 11)과 고배율(도 12)에서 확인하였다.The change in cell morphology after LPS treatment is shown in FIG. 10. As a result, there was no statistically significant morphological difference between each group. At this time, FSC-H (Forward sidescatter-Height) is a measurement of cell size, SSC-H (Sidescatter-Height) is a measurement of intracellular structure change, LPS-pre Jade is jade powder before legislation, and post Jade is jade powder after legislation. . Changes in cell morphology were confirmed at low magnification (FIG. 11) and high magnification (FIG. 12).

옥 분말의 세포독성실험을 수행하였고(도 13), 세포 내 칼슘이온 농도 변화(도 14)를 측정하였다. 그 결과, LPS 처리시 세포 내 칼슘이온 항상성이 깨지는 것을 관찰하였다. 옥가루와 함께 처리시 위의 현상으로부터 보호하는 결과를 관찰하였다. LPS 처리시와 LPS-옥가루 동시 처리시의 세포활성도를 하기 표 1에 기재하였다. Cytotoxicity experiments of jade powder were performed (Fig. 13), and the change in the concentration of calcium ions in the cells (Fig. 14) was measured. As a result, it was observed that the intracellular calcium ion homeostasis was broken during LPS treatment. When treated with jade powder, the result of protection from the above phenomena was observed. Cellular activity at the time of treatment with LPS and at the time of simultaneous treatment with LPS-okgaru is shown in Table 1 below.

세포 생존율(%)Cell viability (%) 대조군Control 90.18±3.0890.18±3.08 LPSLPS 87.70±2.8987.70±2.89 LPS-법제후 옥가루Jade powder after LPS-legal 84.65±2.6484.65±2.64

결론적으로, LPS 처리시 Raw246.7 세포주 (생쥐 대식세포)의 칼슘이온의 항상성 깨지고, 이때 법제 후의 옥가루를 함께 처리하면 칼슘이온의 항상성이 파괴되는 현상을 완화시켜주는 것을 관찰할 수 있었다. 또한 법제 후의 옥가루와 LPS는 Raw 247.7 세포에 처리시 비정상적인 형태적 변화와 세포독성을 유발하지 않는 것을 확인하였다. In conclusion, it was observed that the homeostasis of calcium ions in Raw246.7 cell line (mouse macrophage) was broken when LPS treatment, and at this time, it was observed that treatment with jade powder after the legislation alleviated the destruction of calcium ion homeostasis. In addition, it was confirmed that jade powder and LPS after legislation did not cause abnormal morphological changes and cytotoxicity when treated to Raw 247.7 cells.

<제조예> <Production Example>

실시예 4와 5의 골분화된 골세포 조성물을 함유한 화장수, 유액 및 미용액을 제조하였다.A lotion, emulsion, and essence containing the osteogenic bone cell composition of Examples 4 and 5 were prepared.

<제조예 1> 골세포 조성물을 함유한 화장수 제조<Preparation Example 1> Preparation of lotion containing bone cell composition

95% 에탄올 8g에 폴리피로리돈 0.05g, 올레일알콜 0.1g, 폴리옥시에틸렌모노올레이트 0.2g, 향료 0.2g, 파라옥시안식향산메틸에스테르 0.1g, 소량의 산화방지제, 소량의 색소를 혼합용해 한다. 골세포 조성물 10g, 글리세린 5g을 정제수 85.33g에 용해한 것에 상기 혼합액을 첨가한 후 교반하여 피부개선효과가 있는 화장수를 얻었다.Mix and dissolve 0.05 g of polypyrrolidone, 0.1 g of oleyl alcohol, 0.2 g of polyoxyethylene monooleate, 0.2 g of fragrance, 0.1 g of paraoxybenzoate methyl ester, a small amount of antioxidant, and a small amount of pigment in 8 g of 95% ethanol. . 10 g of the bone cell composition and 5 g of glycerin were dissolved in 85.33 g of purified water, and the mixture was added and stirred to obtain a skin-improving lotion.

<제조예 2> 골세포 조성물을 함유한 유액 제조<Production Example 2> Preparation of emulsion containing bone cell composition

세틸알콜 1.2g, 스쿠알란 10g, 바세린 2g, 파라옥시안식향산에틸에스테르 0.2g, 글리세린모노에스테아레이드 1g, 폴리옥시에틸렌(20몰 부가)모노올레이트 1g및 향료 0.1g을 70℃에서 가열혼합용해하고, 실시예 3에서 수득한 골세포 조성물 0.5g, 디프로필렌글리콜 5g, 폴리에틸렌글리콜-1500 2g, 트리에탄올아민 0.2g, 정제수 76.2g을 75℃로 가열해서 용해시킨다. 양자를 혼합하여 유화시킨 후 냉각하여 수중유(O/W)형의 피부개선효과가 있는 유액을 얻었다.Cetyl alcohol 1.2g, squalane 10g, vaseline 2g, paraoxybenzoic acid ethyl ester 0.2g, glycerin monoesterade 1g, polyoxyethylene (20 mole addition) monooleate 1g and fragrance 0.1g were heated and mixed and dissolved at 70℃. , 0.5 g of the bone cell composition obtained in Example 3, 5 g of dipropylene glycol, 2 g of polyethylene glycol-1500, 0.2 g of triethanolamine, and 76.2 g of purified water were dissolved by heating at 75°C. Both were mixed, emulsified, and then cooled to obtain an oil-in-water (O/W) type emulsion with skin improvement effect.

<제조예 3> 골세포 조성물을 함유한 미용액 제조<Preparation Example 3> Preparation of essence containing bone cell composition

95% 에틸알콜 5g에 폴리옥시에틸렌솔비탄모노올레이트 1.2g, 키툴로오즈 0.3g, 히아루론산나트륨 0.2g, 비타민 E-아세테이트 0.2g, 감초산 나트륨 0.2g, 파라옥시안식향산에틸에스테르 0.1g, 실시예 3에서 수득한 골세포 조성물 1g 및 적량의 색소를 혼합하여 피부개선효과가 있는 미용액을 얻었다.95% ethyl alcohol 5g, polyoxyethylene sorbitan monooleate 1.2g, kitulose 0.3g, sodium hyaluronate 0.2g, vitamin E-acetate 0.2g, sodium licorice 0.2g, paraoxybenzoate ethyl ester 0.1g, practice 1 g of the bone cell composition obtained in Example 3 and an appropriate amount of pigment were mixed to obtain a cosmetic liquid having an effect of improving skin.

<제조예 4> 골세포 조성물에 글리콜산 및 비타민 C가 첨가된 조성물의 제조<Preparation Example 4> Preparation of a composition in which glycolic acid and vitamin C are added to the bone cell composition

상기 골세포 조성물 450g에 글리콜산(글리콜산 99%, Aldrich사제품) 45g 및 비타민C(L-Ascorbic acid, Sigma) 30g을 잘 혼합하였다.45 g of glycolic acid (99% glycolic acid, manufactured by Aldrich) and 30 g of vitamin C (L-Ascorbic acid, Sigma) were well mixed with 450 g of the bone cell composition.

이상, 바람직한 실시예를 들어 본 발명을 상세하게 설명하였으나, 본 발명은 상기 실시예에 한정되는 것은 아니며, 본 발명의 기술적 사상의 범위 내에서 당 분야에서 통상의 지식을 가진 자에 의하여 여러 가지 변형이 가능하다.Above, the present invention has been described in detail with reference to a preferred embodiment, but the present invention is not limited to the above embodiment, and various modifications by those of ordinary skill in the art within the scope of the technical idea of the present invention This is possible.

Claims (6)

1) 50~500 ug/mL 농도의 옥 추출물을 피부세포(Fibroblast)에 처리하여 활성화된 기능성 성분을 배출시키는 단계;
2) 상기 기능성 성분이 포함된 배지의 상층액을 분리하는 단계;
3) 상기 분리된 배지 상층액을 지방유래 줄기세포(ADSC)에 처리하여 배양하여 골세포로 분화시키는 단계; 및
4) 상기 분화된 골세포를 분리하는 단계;를 포함하는 옥추출물에 의한 줄기세포의 골세포 분화 방법.
1) treating the skin cells (Fibroblast) with a jade extract having a concentration of 50 to 500 ug/mL to discharge the activated functional ingredients;
2) separating the supernatant of the medium containing the functional ingredient;
3) treating and culturing the separated medium supernatant on adipose-derived stem cells (ADSC) to differentiate into bone cells; And
4) Separating the differentiated bone cells; Bone cell differentiation method of stem cells by a jade extract comprising.
제 1항에 있어서, 상기 옥 추출물은 옥을 70℃에서 2시간 동안 열수 추출하고 감압농축하는 것을 특징으로 하는 옥추출물에 의한 줄기세포의 골세포 분화 방법.
The method of claim 1, wherein the jade extract extracts jade with hot water at 70° C. for 2 hours and concentrates under reduced pressure.
삭제delete 제 1항에 있어서, 상기 3) 단계의 배양은 1~10일 동안 이루어지는 것을 특징으로 하는 옥추출물에 의한 줄기세포의 골세포 분화 방법.
The method of claim 1, wherein the culture in step 3) is performed for 1 to 10 days.
삭제delete 삭제delete
KR1020200068870A 2020-06-08 2020-06-08 Osteogenesis method by Jade extract in ADSC KR102179155B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200068870A KR102179155B1 (en) 2020-06-08 2020-06-08 Osteogenesis method by Jade extract in ADSC

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200068870A KR102179155B1 (en) 2020-06-08 2020-06-08 Osteogenesis method by Jade extract in ADSC

Publications (1)

Publication Number Publication Date
KR102179155B1 true KR102179155B1 (en) 2020-11-16

Family

ID=73680082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200068870A KR102179155B1 (en) 2020-06-08 2020-06-08 Osteogenesis method by Jade extract in ADSC

Country Status (1)

Country Link
KR (1) KR102179155B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020004300A (en) * 2000-07-04 2002-01-16 김준한 Jade extractant And Process For Preparing Thereof
KR101932973B1 (en) * 2018-10-12 2018-12-27 성보경 Composition for prevention and improvement of periodontal disease or periodontal disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020004300A (en) * 2000-07-04 2002-01-16 김준한 Jade extractant And Process For Preparing Thereof
KR101932973B1 (en) * 2018-10-12 2018-12-27 성보경 Composition for prevention and improvement of periodontal disease or periodontal disease

Similar Documents

Publication Publication Date Title
RU2759508C1 (en) Composition including exosome obtained from stem cells for induction of adipogenic differentiation, regeneration of fat tissue, skin whitening or correction of wrinkles
JP5981947B2 (en) Skin cream
DE60024612T2 (en) METHOD FOR PRODUCING CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS
KR102269612B1 (en) Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation
KR101121154B1 (en) A composition for transplant comprising adipose stem cells or adipocytes
US20210198626A1 (en) Compositions and methods for cell culture
KR20180008526A (en) Compositions comprising mesenchymal stem cells and uses thereof
EP3747478A1 (en) Bioink composition for dermis regeneration sheet, method for manufacturing customized dermis regeneration sheet using same, and customized dermis regeneration sheet manufactured using manufacturing method
AU2023206197A1 (en) Enhanced multipotent cells and microvascular tissue and methods of use thereof
US20180021380A1 (en) Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same
CN106062184B (en) The purposes of Odontogenic cysts stem cell and the Odontogenic cysts stem cell of gene modification
CN112135606A (en) Stem cell filtrate preparation and method for producing the same
US20030202965A1 (en) Methods and compositions for the preparation of cell transplants
KR101746219B1 (en) Composition Containing Keratin-EGCG Complex And Method For Producing The Same
KR20150088374A (en) Stem cell medium containing cell growth factors from human adipose derived stem cells and cosmetic composition for improvement atopic syndrom prepared therefrom
KR102179155B1 (en) Osteogenesis method by Jade extract in ADSC
KR20130021793A (en) Cosmetic composition comprising nano capsule or nanofiber containing cultured medium of adipose-derived adult stem cells and manufacturing method thereof
KR20080068077A (en) Fibroblast activator, method for activation of fibroblast, collagen synthesis promoter, method for promotion of collagen synthesis, skin aging-preventing agent, and method for prevention of aging of the skin
KR101885729B1 (en) Composition including mesenchymal stem cell derived from adipose tissue and hyaluronic acid derivative and method for preparing the same
EP3950934A1 (en) Method for culturing cell population and use thereof
JP2014214094A (en) Cosmetic composition containing liposome including culture solution extract of stem cells derived from human
KR102547244B1 (en) Composition for Inducing Differentiation of Stem Cells into Chondrocytes Comprising the Extract Of Cumin as an Effective Ingredient
RU2679446C2 (en) Method of treatment of diabetic foot syndrome
Moh’d Said The Impact of Hydroxyapatite Nanoparticles on the Cellular Processes of Stem Cells Derived From Dental Tissue Sources
CN118165927A (en) Human umbilical mesenchymal stem cell preparation, preparation method and application thereof in treating knee osteoarthritis

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant